TROY, Mich., Jan. 21 /PRNewswire-FirstCall/ -- Fourth Quarter Highlights -- Record net revenues of $13.7 million, up 21 percent. -- Record income before income taxes of $5.1 million, up 14 percent. -- Net income of $3.3 million, up 19 percent; $0.25 per diluted share. Fiscal 2008 Highlights -- Record net revenues of $47.5 million, up 23 percent. -- Record income before income taxes of $16.4 million, up 10 percent. -- Record net income of $10.4 million, up 8 percent; $0.76 per diluted share. -- Gross margin 87 percent for fiscal 2008 and the fourth quarter. -- Launched its INVOS Cerebral/Somatic Oximeter in the neonatal intensive care unit. Combined pediatric and neonatal sensor revenue was $10.9 million in 2008, up 52 percent. -- Expanded labeling for the INVOS System to allow its use to monitor changes in oxygen saturation in "any tissue" beneath the sensor. In the neonatal patient, customers are placing sensors over various vital organs, such as the brain, kidneys and bowel. -- Acquired ICU Data Systems, Inc. of Gainesville, Fla., a company developing a technology to integrate data from bedside devices into a single display for comparison, data management and data storage.
Somanetics Corporation (Nasdaq: SMTS) today reported financial results for the fourth fiscal quarter and year ended November 30, 2008.
"We achieved our fifth consecutive year of strong growth in revenue and income before income taxes in 2008, reflecting continued market adoption of our INVOS System," said Bruce Barrett, Somanetics' president and CEO. "The more compelling results in 2008 were strategic achievements that create major new opportunities for our business. Our entry into the neonatal ICU and expansion of our labeling more than double the size of our addressable market for the INVOS System. Inclusion of cerebral oximetry in the STS Database puts us on a course that can result in practice standards that establish the technology as standard of care in adult cardiac surgeries. And, the acquisition of ICU Data Systems provides us an additional means to advance and differentiate our INVOS product offering as well as a new product with significant revenue potential."
"We are accelerating investments to capitalize on these new opportunities in the neonatal ICU and with the ICU Data Systems technology," said Barrett. "However, we expect the economic downturn to limit capital spending and slow adoption of new technologies, constraining revenue growth in the near term."
Fourth Quarter Results
Net revenues for the fourth quarter of 2008 increased 21 percent to a record $13.7 million from $11.3 million in the same period of 2007. U.S. net revenues increased 16 percent to $11.0 million from $9.5 million in the same period of 2007. International net revenues increased 51 percent to $2.7 million compared to $1.8 million in the fourth quarter of 2007.
Gross margin was 87 percent compared to 88 percent in the fourth quarter of 2007.
Fourth quarter income before income taxes was a record $5.1 million, compared to $4.5 million in the fourth quarter of 2007. Net income in the fourth quarter of fiscal 2008 was $3.3 million, or $0.25 per diluted share.
Fiscal Year 2008 Results
Fiscal year 2008 net revenues increased 23 percent to a record $47.5 million from $38.6 million a year ago. U.S. net revenues increased 21 percent to $38.0 million and international net revenues increased 34 percent to $9.4 million.
Gross margin was 87 percent, compared to 88 percent in 2007. Income before income taxes increased to a record $16.4 million from $14.9 million in 2007 and net income was a record $10.4 million, or $0.76 per diluted share. Somanetics recognized income taxes at an estimated effective tax rate of 36 percent for 2008.
Somanetics ended fiscal 2008 with cash, marketable securities and long- term investments of $70.0 million and no borrowings.
Somanetics Acquires ICU Data Systems, Inc.
In November 2008, Somanetics acquired substantially all of the assets of Gainesville, Fla.-based ICU Data Systems, Inc., a technology development company, for approximately $2 million in cash plus the assumption of minimal specified liabilities.
ICU Data Systems has developed a patented technology that integrates data
from a broad array of hospital bedside devices, such as physiological
monitors, ventilators and infusion devices, into a single bedside display for
comparison, data management and storage. The patent underlying the technology
was licensed from the
The data integration technology offers Somanetics' customers several benefits, including the ability to easily customize the presentation of data from various bedside devices for comparison on the same display and on the same timeline. Once data from various devices are integrated, customers can also customize the calculation and display of derived parameters, or calculated parameters based on the combination of two or more discrete parameters.
In addition, customers can create user-defined, automated event marks and alerts. All resulting information can be stored for inclusion in the patient record and clinical research.
Somanetics plans to further develop and launch its newly-acquired data integration technology as a stand-alone device in mid-2009. The INVOS System is one of many devices whose data can be integrated into the stand-alone device. To support the addition of the derived parameter features to the system, the Company will pursue a new FDA 510(k) clearance in 2009. In addition, the Company will invest to combine the ICU Data Systems and INVOS System technologies in a single product for launch in the second half of 2010.
"There is an important unmet clinical need in the acute care setting for a more intelligent approach to data integration, presentation and management to support clinical decision making and research," Barrett said. "We believe this new technology will differentiate our INVOS System, accelerate understanding and adoption of the INVOS System and provide us with a new revenue generating product."
Somanetics plans to account for the acquisition by allocating the purchase price to an intangible technology asset of approximately $246,000, which will be amortized over 20 years, with almost all of the balance allocated to Goodwill. In 2009, Somanetics plans to invest approximately $2 million in the product development and launch of the stand-alone system and further development of the technology integrated with the INVOS System. The Company believes the acquisition will be accretive to earnings in 2010.
Neonatal ICU Market Entry
Somanetics obtained FDA clearance to expand its labeling for the INVOS System to support its entry into the neonatal ICU, which began in the first half of 2008. The new labeling provides for monitoring "any tissue" beneath the sensor. In neonates, the tissues beneath the sensor can be vital organs, like the kidney and bowel. Many clinicians in the neonatal ICU apply the INVOS technology to assess changes in kidney and/or bowel oxygen saturation in addition to cerebral oxygen saturation. Somanetics estimates that its entry into the neonatal ICU more than doubles the addressable market for the INVOS System.
Somanetics is supporting its marketing initiatives with clinical research related to the use of the INVOS System in the neonatal ICU. Such research has shown that placing the sensors over the abdomen and flank provides important information about the bowels and kidney, respectively. During the first half of 2009, the data from many of these research projects is expected to be presented at various medical conferences and create significant interest in the INVOS System.
Somanetics also is sponsoring medical education and quality improvement initiatives, particularly quality programs relating to applications of the INVOS System in the neonatal ICU.
"We have an opportunity to make an important contribution to the care of these most vulnerable of patients in the neonatal ICU," Barrett said. "We believe the combination of the INVOS System and the ICU Data Systems technology, along with our evidence-based approach, intellectual property and medical education support, position us to lead this market."
Sales and Marketing Developments
In the U.S., Somanetics plans to significantly increase its investment in medical education to develop the neonatal ICU market. These plans include increasing its U.S. field clinical specialist team by 15 members in the first half of 2009 to 37 and increasing its investment in marketing and medical education focused on the neonatal ICU by approximately $1 million. Somanetics also plans to add two new U.S. sales employees to bring the total to 33 and hire several international sales employees to support its distributor's efforts with the INVOS System and to lead the launch of the new data integration technology.
In early 2008, The Society of Thoracic Surgeons (STS) began collecting cerebral oximetry information as part of its STS Adult Cardiac Surgery Database, which is used to develop practice standards intended to improve quality and safety.
"We continue to believe this data, which is expected to be reviewed, analyzed, presented and published over the next two years, if consistent with prior data, has the potential to drive further adoption of the INVOS System in cardiac surgery and establish our technology as a standard of care for this patient population," Barrett said.
Somanetics' financial guidance for fiscal year 2009 is based on market and economic conditions, including the assumption that the current economic downturn continues throughout 2009. Current estimates reflect management's plan to invest in the clinical research, medical education and research and development projects focused on the pediatric and neonatal ICU markets, the development of the ICU Data Systems technology and the addition of several international sales employees. Somanetics undertakes no obligation to update its estimates. Somanetics is currently forecasting:
-- Fiscal 2009 net revenues of approximately $54.6 million, a 15 percent increase over 2008. -- Gross margin of approximately 86 percent and operating margin of approximately 20 percent. -- Fiscal 2009 income before income taxes of approximately $12 million.
Somanetics to Host Conference Call
Somanetics will web cast its fiscal 2008 conference call at 10:00 a.m. (ET) today. To join the web cast, visit the Investor Center section of Somanetics' website at www.somanetics.com and click on the "2008 Year-End Conference Call" link. The call also will be archived on the website.
Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS(R) Cerebral/Somatic Oximeter, a non-invasive patient monitoring system that continuously measures changes in the blood oxygen levels in the brain and elsewhere in the body in patients with or at risk for restricted blood flow. Surgeons, anesthesiologists and other medical professionals can use the information provided by the INVOS System, in conjunction with other available information, to identify oxygen imbalances in tissues beneath the sensor and take necessary corrective action, potentially improving patient outcomes and reducing the costs of care. The INVOS System has an 11-year market track record supported by more than 600 clinical references, and is used at more than 700 U.S. hospitals. Somanetics recently acquired ICU Data Systems Inc., a company developing a technology that integrates data from bedside devices into a single display for comparison, data management and data storage. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in Europe, Canada, the Middle East and South Africa and Edwards Lifesciences represents INVOS System products in Japan. For more information visit www.somanetics.com.
Except for historical information contained herein, the matters discussed in this news release, including financial guidance for fiscal year 2009, are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Actual results may differ significantly from results discussed in the forward-looking statements and may be affected by, among other things, economic conditions in general and in the healthcare market, the demand for and market acceptance of our products in existing market segments and in new market segments we plan to pursue, our current dependence on the Cerebral Oximeter and disposable sensors, our dependence on distributors for a substantial portion of our sales, our dependence on single-source suppliers, potential competition, the effective management of our growth, our ability to attract and retain key personnel, the potential for products liability claims, government regulation of our business, changes in our deferred tax assets, future equity compensation expenses, the challenges associated with developing new products and obtaining and maintaining regulatory approvals if necessary, research and development activities, the lengthy sales cycle for our products, sales employee turnover, changes in our actual or estimated future taxable income, changes in accounting rules, enforceability and the costs of enforcement of our patents, potential infringements of others' patents and the other factors set forth from time to time in Somanetics' Securities and Exchange Commission filings, including Somanetics' 2007 Annual Report on Form 10-K filed on February 6, 2008 and its 2008 Quarterly Reports on Form 10-Q filed on April 2, 2008, June 30, 2008 and September 30, 2008, respectively.
(Tables to follow) BALANCE SHEETS November 30, 2008 2007 ASSETS CURRENT ASSETS: Cash and cash equivalents $37,166,141 $33,172,977 Marketable securities 19,992,545 18,978,074 Accounts receivable 7,862,103 7,486,571 Inventory 2,960,422 1,998,284 Prepaid expenses 597,460 560,885 Accrued interest receivable 16,667 551,117 Deferred tax asset - current 164,615 3,069,929 Total current assets 68,759,953 65,817,837 PROPERTY AND EQUIPMENT: Demonstration and no capital cost sales equipment at customers 3,919,296 3,386,287 Machinery and equipment 1,638,597 1,531,387 Furniture and fixtures 504,485 307,919 Leasehold improvements 197,450 196,700 Total 6,259,828 5,422,293 Less accumulated depreciation and amortization (3,418,697) (2,931,596) Net property and equipment 2,841,131 2,490,697 OTHER ASSETS: Long-term investments 12,837,710 33,653,099 Deferred tax asset -- non-current 1,587,977 3,004,755 Intangible assets, net 246,318 3,097 Goodwill 1,679,713 -- Other 15,000 15,000 Total other assets 16,366,718 36,675,951 TOTAL ASSETS $87,967,802 $104,984,485 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $1,271,058 $1,118,003 Accrued liabilities 1,848,672 1,701,481 Total current liabilities 3,119,730 2,819,484 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred shares; authorized, 1,000,000 shares of $.01 par value; no shares issued or outstanding -- -- Common shares; authorized, 20,000,000 shares of $.01 par value; issued and outstanding, 12,034,074 shares at November 30, 2008, and 13,443,961 shares at November 30, 2007 120,341 134,440 Additional paid-in capital 91,330,305 119,079,383 Accumulated deficit (6,602,574) (17,048,822) Total shareholders' equity 84,848,072 102,165,001 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $87,967,802 $104,984,485 STATEMENTS OF OPERATIONS For the Years Ended November 30, 2008 2007 NET REVENUES $47,455,617 $38,585,832 COST OF SALES 6,249,256 4,726,146 Gross margin 41,206,361 33,859,686 OPERATING EXPENSES: Research, development and engineering 1,259,227 668,815 Selling, general and administrative 26,166,120 22,269,184 Total operating expenses 27,425,347 22,937,999 OPERATING INCOME 13,781,014 10,921,687 OTHER INCOME: Interest income 2,629,967 4,008,537 Total other income 2,629,967 4,008,537 INCOME BEFORE INCOME TAXES $16,410,981 $14,930,224 INCOME TAX EXPENSE (5,964,734) (5,247,943) NET INCOME $10,446,247 $9,682,281 NET INCOME PER COMMON SHARE -- BASIC $.82 $.73 NET INCOME PER COMMON SHARE -- DILUTED $.76 $.67 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING -- BASIC 12,671,452 13,213,428 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING -- DILUTED 13,671,730 14,384,445 STATEMENTS OF OPERATIONS For the Fourth Quarter Ended November 30, 2008 2007 NET REVENUES $13,654,292 $11,275,273 COST OF SALES 1,835,318 1,338,888 Gross margin 11,818,974 9,936,385 OPERATING EXPENSES: Research, development and engineering 364,654 233,370 Selling, general and administrative 6,742,584 6,234,820 Total operating expenses 7,107,238 6,468,190 OPERATING INCOME 4,711,736 3,468,195 OTHER INCOME: Interest income 432,687 1,033,702 Total other income 432,687 1,033,702 INCOME BEFORE INCOME TAXES $5,144,423 $4,501,897 INCOME TAX EXPENSE (1,825,311) (1,702,312) NET INCOME $3,319,112 $2,799,585 NET INCOME PER COMMON SHARE -- BASIC $.28 $.21 NET INCOME PER COMMON SHARE -- DILUTED $.25 $.19 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING -- BASIC 12,012,096 13,331,076 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING -- DILUTED 13,071,397 14,542,444
|SOURCE Somanetics Corporation|
Copyright©2009 PR Newswire.
All rights reserved